By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
GMJ NewsGMJ NewsGMJ News
  • Latest News
    • GMJ Briefs
  • Podcast & Media
    • Podcast Episodes
    • GMJ Audio
    • GMJ Videos
  • Research Digest
    • New Studies
    • Georgian Research
    • Data & Numbers
  • Policy & Systems
    • Health Policy
    • Quality & Safety
    • Migration & Health
    • Global Health
  • Practice
    • Clinical Updates
    • Case Discussions
    • Pharmacy & Prescribing
    • Ingredients A-Z
  • Perspectives
    • Editorial
    • Explainers
    • Voices
    • Letters
  • GMJ Articles
    • Vol. 1 Issue 2 (2026)
    • Vol. 1 Issue 1 (2026)
    • Pre-Launch Articles (2025)
  • Read the Journal →
  • About GMJ News
Notification Show More
Font ResizerAa
GMJ NewsGMJ News
Font ResizerAa
  • Latest News
    • GMJ Briefs
  • Podcast & Media
    • Podcast Episodes
    • GMJ Audio
    • GMJ Videos
  • Research Digest
    • New Studies
    • Georgian Research
    • Data & Numbers
  • Policy & Systems
    • Health Policy
    • Quality & Safety
    • Migration & Health
    • Global Health
  • Practice
    • Clinical Updates
    • Case Discussions
    • Pharmacy & Prescribing
    • Ingredients A-Z
  • Perspectives
    • Editorial
    • Explainers
    • Voices
    • Letters
  • GMJ Articles
    • Vol. 1 Issue 2 (2026)
    • Vol. 1 Issue 1 (2026)
    • Pre-Launch Articles (2025)
  • Read the Journal →
  • About GMJ News
Follow US
GMJ News > Drugs A-Z > ARB > Azilsartan

Azilsartan

GMJ
Last updated: 02/06/2026 14:31
By
Prof. Giorgi Pkhakadze
Share
5 Min Read
SHARE
3 min read|598 words

What is Azilsartan?

Azilsartan is an oral medication that belongs to a class of drugs called angiotensin receptor blockers (ARBs). It is primarily prescribed to treat high blood pressure (hypertension) in adults by helping blood vessels relax and widen. This medication is often used when other blood pressure medications have not been effective or have caused unacceptable side effects.

Uses

  • Hypertension: Primary indication for treating high blood pressure in adults, helping to reduce cardiovascular risk
  • Cardiovascular protection: May help reduce the risk of heart attack and stroke in patients with hypertension
  • Kidney protection: Can help protect kidney function in diabetic patients with high blood pressure
  • Heart failure management: Sometimes used as part of combination therapy for certain heart failure patients
  • Diabetic nephropathy: May slow progression of kidney disease in diabetic patients with protein in their urine

How it works

Azilsartan blocks the action of angiotensin II, a hormone that causes blood vessels to narrow and constrict. By preventing angiotensin II from binding to its receptors in blood vessel walls, azilsartan allows vessels to remain relaxed and dilated. This reduction in blood vessel resistance leads to lower blood pressure and improved blood flow throughout the body.

Side effects

Common side effects:

  • Dizziness or lightheadedness
  • Fatigue or weakness
  • Diarrhea
  • Headache
  • Nausea
  • Cough
  • Back pain
  • Muscle cramps

Serious side effects to watch for:

Submit Your Paper
GMJ_Submit_Banner
  • Severe dizziness or fainting
  • Signs of kidney problems (changes in urination, swelling)
  • Hyperkalemia (high potassium levels)
  • Severe allergic reactions (difficulty breathing, swelling of face or throat)
  • Liver problems (yellowing of skin or eyes, dark urine)

Warnings and precautions

  • Pregnancy: Should not be used during pregnancy, especially in the second and third trimesters, as it can cause serious harm to the developing fetus including kidney problems and death
  • Kidney disease: Requires careful monitoring and possible dose adjustment in patients with existing kidney impairment or kidney artery stenosis
  • Liver disease: Use with caution in patients with liver problems, as the drug is processed through the liver
  • Dehydration: Patients who are volume-depleted or dehydrated may experience severe blood pressure drops when starting treatment
  • Elderly patients: May be more sensitive to blood pressure-lowering effects and require lower starting doses

Interactions

  • Potassium supplements and salt substitutes: May increase potassium levels to dangerous amounts when combined with azilsartan
  • Diuretics: Can enhance blood pressure-lowering effects, potentially causing excessive drops in blood pressure
  • NSAIDs (ibuprofen, naproxen): May reduce the effectiveness of azilsartan and increase kidney damage risk
  • Lithium: Azilsartan may increase lithium levels in the blood, leading to toxicity
  • ACE inhibitors: Combining with azilsartan may increase risk of kidney problems and high potassium
  • Aliskiren: Should not be used together in diabetic patients due to increased risk of kidney problems and high potassium
  • Warfarin: May require monitoring of blood clotting times as effects could be altered
  • Digoxin: Azilsartan may slightly increase digoxin levels requiring monitoring

Check interactions with the GMJ Interaction Checker

Dosage

The typical starting dose for adults is 40 mg once daily, which can be increased to a maximum of 80 mg once daily if needed for blood pressure control. The medication can be taken with or without food at the same time each day. Patients with kidney impairment may require lower starting doses. For elderly patients or those taking high-dose diuretics, a lower starting dose of 20 mg once daily may be considered. All dosage adjustments should be made gradually and under medical supervision, as individual response to treatment varies significantly.

Sources: FDA DailyMed drug labels (public domain), BNF, WHO Essential Medicines List. This article is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting or stopping any medication.

Cite this page

GMJ News Desk. "Azilsartan." GMJ News — Georgian Medical Journal, 2 June 2026. https://news.gmj.ge/drug/azilsartan/

CC BY 4.0This work is licensed under Creative Commons Attribution 4.0 International (CC BY 4.0). You are free to share and adapt this content with attribution to GMJ News (news.gmj.ge).

Was this article helpful?

Related topics

Optional further reading from the GMJ knowledge base.

AzilsartanDrug
Share This Article
Facebook LinkedIn Bluesky Copy Link Print
GMJ
ByProf. Giorgi Pkhakadze
Follow:
Prof. Giorgi Pkhakadze, MD, MPH, PhD, is Editor-in-Chief of the Georgian Medical Journal and Chair of the Public Health Institute of Georgia (PHIG). He is Professor and Head of the Department of Social and Behavioural Sciences at David Tvildiani Medical University, and Secretary/Treasurer of the UEMS Section of Public Health. ORCID: 0000-0001-7609-4515.

Submit Your Paper →

Georgia's peer-reviewed open-access medical journal. No APC until January 2027.
Submit Manuscript →
The Case for ‘Health Care’: Why Language Precision Matters in Medical Journalism

STAT News's recent reader poll found that approximately 60% of respondents prefer…

UK Public Health Laboratory in Birmingham Releases Updated User Handbook for NHS Services

The UK Health Security Agency has released an updated user handbook for…

UK Health Security Agency Launches Evidence-Based Training Programme for Healthcare Staff

The UK Health Security Agency has launched a structured training programme to…

Submit Your Paper to GMJ

No APC until January 2027.
Submit Manuscript →

You Might Also Like

Valsartan

By
Prof. Giorgi Pkhakadze
01/06/2026

Losartan

By
Prof. Giorgi Pkhakadze
01/06/2026

Azilsartan

By
Prof. Giorgi Pkhakadze
02/06/2026

Candesartan

By
Prof. Giorgi Pkhakadze
02/06/2026
Facebook Twitter Youtube Instagram
Company
  • Privacy Policy
  • Contact US
  • GMJ Journal
  • Submit Manuscript
  • Editorial Team
  • Register at GMJ
  • Terms of Use

Subscribe to GMJ News — Click here

Join Community
© 2026 Georgian Medical Journal (GMJ). Published by the Public Health Institute of Georgia (PHIG). All rights reserved.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?

Not a member? Sign Up